Vaccine News and Research

Latest Vaccine News and Research

Effective infant vaccination against pneumonia needed in sub-Saharan Africa

Researchers at the University of Warwick, and the Kenya Medical Research Institute, Kilifi, Kenya, have found that respiratory syncytial virus (RSV) appears to be the predominant virus detected among infants and children hospitalized in Kenya with severe pneumonia, according to a study in the May 26 issue of JAMA. The contribution to this severe disease by an individual pathogen stresses the need for effective infant vaccination.

28 May 2010

Not all strains of influenza die off at the end of winter, reveals genetic analysis

Every autumn, as predictably as falling leaves, flu season descends upon us. Every spring, just as predictably, the season comes to a close. This cyclical pattern, common in temperate regions, is well known, but the driving forces behind it have been in question.

28 May 2010

Biomedical engineering professor receives Transition Career Development Award

Biomedical engineering professor David Zaharoff has been awarded a Transition Career Development Award by the National Cancer Institute to further his research on Interleukin-12, a powerful cytokine that shows great promise for therapeutic treatment of numerous types of cancer.

28 May 2010

Small molecule ramps up interferon production in host cells, launching potent immune response

Many disease-causing microbes carry pumps that expel antibiotics, making the bugs hard to kill with standard drugs. Ironically, these same pumps could be the bugs' Achilles heel.

28 May 2010

Researchers study safety and immunogenicity of two H1N1 vaccines in UK children

The first head to head study of the two H1N1 vaccines used in the UK during the recent pandemic finds that the adjuvanted split virus vaccine induced higher immune response rates in young children, but was associated with more reactions than the whole virus vaccine.

28 May 2010

The Wistar Institute Melanoma Research Center launched to develop new therapies for melanoma

In an effort to meet the rising rates of melanoma head-on, The Wistar Institute today announced the creation of The Wistar Institute Melanoma Research Center. The Center brings together scientists, physicians, the life sciences industry, and melanoma advocates in saving lives by advancing new and better therapies for this deadly disease.

28 May 2010

ART associated with reduced risk of HIV transmission to sexual partners, study shows

Research published in the Lancet online Thursday "provides the strongest evidence to date" that antiretroviral therapy might also be used to prevent transmission of HIV, Agence France-Presse reports. The observational study found that treating HIV-positive patients with ART reduced the risk of HIV transmission to their sexual partners by 92 percent (5/26).

28 May 2010

ARCA receives approval to begin enrollment of first therapeutic trial with GeoVax vaccine

GeoVax Labs, Inc., a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announced today The AIDS Research Consortium of Atlanta has received approval to begin enrollment of the first therapeutic trial ever conducted using a promising HIV vaccine candidate from GeoVax, Inc.

28 May 2010

HZI researchers develop new method to produce insulin for treatment of diabetes

More than eight million diabetics live in Germany. Diabetes is not restricted to our prosperous society and the highest growth rates often occur in countries with aspiring economies such as in Asia. Worldwide, more than 285 million people suffer from this illness; with 50 million diabetics, India is the country with the most people affected by this disease.

27 May 2010

Modified measles virus may hold potential for treatment of medulloblastoma

The use of modified measles virus may represent a new treatment for a childhood brain tumor known as medulloblastoma, according to a new study appearing in Neuro-Oncology.

27 May 2010

Space Shuttle Atlantis returns from International Space Station with tenth scientific payload for Astrogenetix

Space Shuttle Atlantis returned from the International Space Station (ISS) landing at the Kennedy Space Center this morning with the tenth scientific payload for Astrogenetix, a commercial biotech company based out of Austin, Texas. Astrogenetix is conducting research on methicillin-resistant Staphylococcus aureus (MRSA) as part of the ISS National Laboratory Pathfinder Vaccine (NLP-V) missions.

27 May 2010

Nottingham scientists given green light to test new vaccine for malignant melanoma

Nottingham scientists have been given the green light to test a vaccine which they hope could reverse, and even cure malignant melanoma, the most deadly type of skin cancer.

27 May 2010

Experimental Hendra virus treatment offered to mother and daughter

After recent reports of a horse being put down for being infected with the deadly Hendra virus, new reports of an experimental treatment have surfaced. At Queensland's Sunshine Coast a mother and daughter duo, Rebecca Day and her 12 year old girl Mollie, who had been exposed to the virus, have been offered the experimental treatment.

27 May 2010

A step closer to a universal influenza virus vaccine

Researchers at Mount Sinai School of Medicine have developed a new influenza vaccine that brings science one step closer to a universal influenza vaccine that would eliminate the need for seasonal flu shots. The new findings can be found in the inaugural issue of mBio-, the first online, open-access journal published by the American Society for Microbiology.

26 May 2010

RSV appears to be predominant among Kenyan children hospitalized with severe pneumonia: Study

Among infants and children hospitalized in Kenya with severe pneumonia, respiratory syncytial virus appears to be the predominant virus detected, according to a study in the May 26 issue of JAMA.

26 May 2010

CEVEC, Pevion Biotech sign license option agreement for transient CAP-T cell expression technology

CEVEC Pharmaceuticals, the German developer of a novel human expression system derived from amniocytes, announced today the signing of an exclusive license option agreement with Pevion Biotech, the Swiss vaccine company. The agreement enables Pevion Biotech to exclusively use CEVEC's transient CAP-T™ cell expression technology to manufacture and commercialize a protein antigen for vaccination against a widespread human infectious disease.

26 May 2010

Consequences of secrecy in medicine

No one knows how many mothers' and babies' lives have been saved by the obstetrical forceps. This device has been part of the standard equipment of every maternity room for about 250 years. However, a shadow lies over the success story: after the Chamberlen brothers developed the device at the beginning of the 17th century, the brothers and their descendants used it for 3 generations, but kept it a secret from other obstetricians.

26 May 2010

Epeius Biotechnologies announces Phase I/II study results of Rexin-G and Reximmune-C for cancer immunotherapy

Epeius Biotechnologies Corporation today announces the clinical results of the study entitled "A Phase I/II Study of Intravenous Rexin-G and Reximmune-C for Cancer Immunotherapy: The GeneVieve Protocol" at the ASCO Annual Meeting on June 6, 2010. The presentation will be made by Dr. Jorge G. Ignacio, Chairman of the Cancer Institute and Bioethics Committee-Philippine General Hospital, and Principal Investigator of the study.

25 May 2010

Vical receives $4.0M grant to support development of novel vaccine for CMV infection

Vical Incorporated announced today that the company is collaborating with leading pediatric infectious disease researchers Stuart P. Adler, M.D., and Michael A. McVoy, Ph.D., of Virginia Commonwealth University under a five-year, approximately $4.0 million grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

25 May 2010

New research finding may change direction of vaccine research for M. tuberculosis

Scientists at NYU Langone Medical Center have discovered that the strategy of "immune evasion" common to many viruses, bacteria and parasites, is uncommon to M. tuberculosis where the antigens remain strikingly unchanged and homogenous. The study published in Nature Genetics on May 23, 2010, suggests that M. tuberculosis antigens do not mutate because they hope to be recognized by the body's immune system- perhaps because the host immune mechanism that leads to the typical lung destruction and cough can contribute to the spread of the disease.

25 May 2010

Vaccine News and Research

Latest Vaccine News and Research

Effective infant vaccination against pneumonia needed in sub-Saharan Africa

Not all strains of influenza die off at the end of winter, reveals genetic analysis

Biomedical engineering professor receives Transition Career Development Award

Small molecule ramps up interferon production in host cells, launching potent immune response

Researchers study safety and immunogenicity of two H1N1 vaccines in UK children

The Wistar Institute Melanoma Research Center launched to develop new therapies for melanoma

ART associated with reduced risk of HIV transmission to sexual partners, study shows

ARCA receives approval to begin enrollment of first therapeutic trial with GeoVax vaccine

HZI researchers develop new method to produce insulin for treatment of diabetes

Modified measles virus may hold potential for treatment of medulloblastoma

Space Shuttle Atlantis returns from International Space Station with tenth scientific payload for Astrogenetix

Nottingham scientists given green light to test new vaccine for malignant melanoma

Experimental Hendra virus treatment offered to mother and daughter

A step closer to a universal influenza virus vaccine

RSV appears to be predominant among Kenyan children hospitalized with severe pneumonia: Study

CEVEC, Pevion Biotech sign license option agreement for transient CAP-T cell expression technology

Consequences of secrecy in medicine

Epeius Biotechnologies announces Phase I/II study results of Rexin-G and Reximmune-C for cancer immunotherapy

Vical receives $4.0M grant to support development of novel vaccine for CMV infection

New research finding may change direction of vaccine research for M. tuberculosis

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in